138227-69-7

Basic information

• Product Name: 1-N-BOC-4-(4-AMINO-2-METHYLPHENOXY)PIPERIDINE
• Synonyms: 1-N-BOC-4-(4-AMINO-2-METHYLPHENOXY)PIPERIDINE;4-(4-AMINO-2-METHYL-PHENOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-Boc-4-(4-amino-2-methylphenoxy)piperidine;tert-butyl 4-(4-amino-2-methylphenoxy)piperidine-1-carboxylate
• CAS NO: 138227-69-7
• Molecular Formula: C₁₇H₂₆N₂O₃
• Molecular Weight: 306.4
• Mol File: 138227-69-7.mol

Chemical Properties

• Boiling Point: 439.396°C at 760 mmHg
• Flash Point: 219.539°C
• Appearance: /
• Density: 1.123g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.549
• CAS DataBase Reference: 1-N-BOC-4-(4-AMINO-2-METHYLPHENOXY)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-BOC-4-(4-AMINO-2-METHYLPHENOXY)PIPERIDINE(138227-69-7)
• EPA Substance Registry System: 1-N-BOC-4-(4-AMINO-2-METHYLPHENOXY)PIPERIDINE(138227-69-7)

Safety Data

• Hazardous Substances Data: 138227-69-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-N-BOC-4-(4-AMINO-2-METHYLPHENOXY)PIPERIDINE is used as a synthetic intermediate for the development of new pharmaceuticals, leveraging its structural complexity and functional groups to create molecules with potential therapeutic applications. Its versatility allows for the synthesis of a wide range of bioactive compounds that can target various biological pathways and diseases.
Used in Organic Synthesis:
In the field of organic synthesis, 1-N-BOC-4-(4-AMINO-2-METHYLPHENOXY)PIPERIDINE serves as a key component in the assembly of complex organic molecules. Its presence facilitates the construction of intricate molecular architectures that can exhibit a range of pharmacological or biological activities, making it an invaluable tool for researchers in medicinal chemistry and related disciplines.
While the provided materials do not specify particular applications beyond its use as a building block in organic synthesis and pharmaceutical development, the compound's structural features suggest potential uses in various industries where novel bioactive molecules are in demand. Its applications could be expanded based on further research into its specific biological activities and interactions.

InChI:InChI=1/C17H26N2O3/c1-12-11-13(18)5-6-15(12)21-14-7-9-19(10-8-14)16(20)22-17(2,3)4/h5-6,11,14H,7-10,18H2,1-4H3

Upstream product

• 138227-68-6 1-tert-butyloxycarbonyl-4-(4-nitro-2methylphenyloxy)piperidine 
• 141-78-6 ethyl acetate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 455-88-9 5-nitro-2-fluorotoluene 

Downstream Products

• 799242-51-6 4-[4-(6-fluoro-pyrido[3,4-d]pyrimidin-4-ylamino)-2-methyl-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester 
• 337519-92-3 ethyl N-[4-(1-t-butoxycarbonylpiperidin-4-yloxy)-3-methylphenyl]sulfamoylacetate 
• 807319-25-1 C₂₆H₃₄N₄O₅ 
• 807319-24-0 C₂₂H₂₆N₄O₃ 

Relevant articles and documents

Cinnamyl derivatives: Synthesis and factor Xa (FXa) inhibitory activities

To develop a potent and oral anticoagulant, a series of compounds with cinnamyl moiety was synthesized and their factor Xa (FXa) inhibitory activities were examined. As a result, some cinnamyl derivatives showed potent FXa inhibitory activities in vitro. Among them, compounds with substituent at the 3-position on the central benzene ring represented by (N-{4-[1-(acetimidoyl) piperidin-4-yloxy]-3-chlorophenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl] sulfamoyl)acetic acid dihydrochloride (45b) and (N-{4-[1-(acetimidoyl)piperidin- 4-yloxy]-3-carbamoylphenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl]sulfamoyl) acetic acid dihydrochloride (45j) exhibited potent FXa inhibitory activities with IC50 values of less than 10 nM in vitro. These compounds also showed potent anticoagulant activities both in vitro and ex vivo. Furthermore, these compounds exhibited no lethal toxicity (30 mg/kg, i.v.).

The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer

The synthesis and biological evaluation of potent and selective inhibitors of the erbB2 kinase is presented. Based on the 4-anilinoquinazoline chemotype, the syntheses of several new series of erbB2 inhibitors are described with quinazoline and pyrido[4,3

BENZAMIDINE DERIVATIVE

Compounds of general formula (1) and pharmacologically acceptable salts thereof: ???[wherein ??????R1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; ??????R2 represents a hydrogen atom or a halogen atom; ??????R3 represents a hydrogen atom, an alkyl group which may be substituted, an aralkyl group, an alkylcarbonyl group which may be substituted, an alkylsulfonyl group which may be substituted or the like; ??????each of R4 and R5 represents a hydrogen atom, a halogen atom, an alkyl group which may be substituted, a carbamoyl group or the like; ??????R6 represents a heterocycle or the like; ??????each of R7 and R8 represents a hydrogen atom, an alkyl group or the like; ??????n represents 0, 1 or 2] ???exhibit excellent activated blood coagulation factor X inhibitory activity and are useful for the prevention or treatment of blood coagulation-related diseases.

BENZAMIDINE DERIVATIVES

Benzamidine derivatives of formula (I) or pharmaceutically acceptable salts thereof exhibit excellent inhibitory activity against factor Xa and are useful for treating or preventing blood coagulation disorders: wherein R 1represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; R 2represents a hydrogen atom, a halogen atom or an alkyl group, R 3represents a hydrogen atom, an optionally substituted alkyl group, an aralkyl group, an optionally substituted alkanoyl group or an optionally substituted alkylsulfonyl group, R 4and R 5 are the same as or different from each other and each represent a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkoxy group, a carboxyl group, an alkoxycarbonyl group or an optionally substituted carbamoyl group, and R 6represents a substituted pyrrolidine group or substituted piperidine group.

Aminobenzene compounds to prevent nerve cell degradation

A compound useful for central antioxidant having inhibitory activity of degeneration and necrocytosis of cerebral cells of the formula (I): STR1 wherein A and B are independently (1) a group of the formula: STR2 wherein R1 and R2 are independently hydrogen atom, an optionally substituted hydrocarbon residue or an optionally substituted heterocyclic group, or R1 together with R2 and the nitrogen atom to which they are bound may form a cyclic amino group, provided that both R1 and R2 are not hydrogen atom at the same time, or (2) a group of the formula: STR3 wherein D is O or S, R3 is hydrogen atom, an optionally substituted hydrocarbon residue or an optionally substituted acyl group, m is 1, 2, or 3 and n is 0, 1, 2, 3 or 4; p is 1 or 2, provided that both A may be the same or different when p is 2; and R4, R5 and R6 are independently hydrogen atom, a lower alkyl or a lower alkoxy, or R5 and R6 may bond together to form --CH=CH--CH=CH--, or a salt thereof.